The QbD Group acquires regulatory affairs and pharmacovigilance company EUDRAC Ltd.
The QbD Group, a privately held company offering comprehensive support to life science companies throughout the entire product lifecycle, today announced the acquisition of EUDRAC Ltd., a specialist regulatory and pharmacovigilance consultancy.
EUDRAC Ltd. provides a bespoke consultancy service throughout product development, regulatory approval, market launch, and into life cycle management. Their success is built upon strong relationships with EMA and MHRA and experience across a wide range of therapeutic areas, pharmaceutical forms, and in-depth knowledge of legislation and guidance.
Joining the QbD Group will allow EUDRAC Ltd. access to a broader client base and the infrastructure necessary to ensure continued growth. EUDRAC Ltd. will be renamed QbD Ltd.
In turn, this acquisition will expand the QbD Group’s regulatory affairs division to better serve its pharmaceutical customers, including those developing advanced therapy medicinal products (ATMPs).
“We’re delighted to bring our expertise into the QbD group. This is the right time for us to make this step and will allow us to benefit from the synergies the acquisition will bring. In addition to bringing opportunities for business growth, it will give our team of experts opportunities to broaden their knowledge and skills.” says Carole Pugh, Managing Director of Eudrac Ltd.
Bart Van Acker, CEO of QbD, adds: “The QbD Group is continuously expanding our already broad ecosystem through strategic alliances and acquisitions. The addition of EUDRAC Ltd. takes us yet another step closer to our QbDream of offering a comprehensive range of skills and expertise to support product development throughout the life sciences.”
Since 2011, QbD has been providing quality solutions for product development and manufacturing. The QbD Group’s team offers the skills and expertise for solving complex problems for companies active in the life sciences. The QbD Group is headquartered in Belgium and has over 450 consultants worldwide in the Netherlands, Spain, France, the UK, Switzerland, Mexico, Colombia, and the US.
QbD Group offers life science companies a range of services from idea to patient.
Related News
ArtiQ joins forces with Clario in strategic acquisition deal to transform respiratory solutions
Leuven models help unlock the dark part of space in the largest European Space Agency mission ever
QbD Chair for Precision Oncology Research in Glioblastoma extended for three years
Zeopore is making its mark in emerging green applications through catalyst optimization leadership
Leuven-based hydrogen panels become an official KU Leuven spin-off
Leuven's imec research centre targets 1950 new hires by 2035
Materialise plays crucial role in world's first-ever eye transplant
KU Leuven students win the world championships for solar cars!
Leuven-based VirusBank Platform enhances society's preparedness against future viral epidemics and pandemics
Leuven's Centre for Drug Design and Discovery (CD3) raises € 70.5 Million
International School in Leuven opens new school building for children of expats
Qaelum NV Partners with I-MED Radiology Network to Enhance Patient Dose Analysis and Incident Reporting in the ANZ Region
How can we help?
The Leuven MindGate team is at your disposal for any questions about the Leuven Innovation Region. Do you want to invest, work or study in the region? We can help you find your way.
We also facilitate collaboration and innovation between companies, knowledge institutes and government within the Leuven Innovation Region, and we are happy to guide any of these stakeholders towards innovation.